Main Article Content
Background. The purpose of the study was to assess the presence of excess body weight, abdominal obesity (AO), and type 2 diabetes mellitus (DM) in oncological diseases in women of young and middle age. Materials and methods. 32 outpatient women aged 31 to 59 years with a verified oncological disease were examined. Standard clinical methods of investigation, statistical processing of results by nonparametric statistics were used. Results. Cervical cancer was verified in 24 (75.0 %) persons, breast adenocarcinoma — in 5 (15.6 %), rectal cancer — in 3 (9.4 %) patients. Elevated body mass index was detected in 24 (75.0 %) women: excess body weight — in 11 (34.4%), AO stage I — in 8 (25.0%), stage II — in 5 persons (15.6 %). Overweight or AO were detected in 30 (93.8 %) patients according to waist-to-height ratio. Type 2 DM was detected only in 2 patients (6.3 %). A heredity in oncopathology was recorded in half of women, of them for AO — in 8 (25.0 %), for type 2 DM — in 5 (15.6 %) patients. A direct correlation was established between heredity in oncological disease and body weight (r = 0.62, p < 0.01), waist circumference (r = 0.61, p < 0.01), body mass index (r = 0.66, p < 0.01), waist-to-height ratio (r = 0.49, p <0.05), waist circumference/hip circumference ratio (r = 0.41, p < 0.01). Conclusions. Overweight and obesity are common among women with cancer, especially, with cervical cancer. Correlation between increased anthropometric indicators and a family history of oncological diseases among women was noted. For comprehensive diagnosis of overweight, in addition to the standard anthropometric indicators, the waist-to-height ratio should be used, as well as additional examinations to detect type 2 DM, insulin resistance, metabolic changes.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Pankiv VI. Advantages of the combined therapy with metformin and glimepiride in patients with type 2 diabetes mellitus. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(2):118-122. doi: 10.22141/2224-07188.8.131.527.100598. (in Ukrainian).
Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014 Aug 30;384(9945):755-65. doi: 10.1016/S0140-6736(14)60892-8.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998 Sep.
Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to antineoplastic effects of metformin in vivo. Oncogene. 2011 Mar 10;30(10):1174-82. doi: 10.1038/onc.2010.483.